Endocrine Abstracts

Prader–Willi syndrome (PWS) is a complex genetic disorder caused by the absence of normal activity in the paternally expressed genes from chromosome 15q11–q13. PWS is characterised by hyperphagia, muscular hypotonia, developmental and cognitive delays, behavioural problems and endocrine abnormalities. Obesity and short stature are common.Endocrine deficiencies: The combination of the phenotype and reduced GH and IGF1 levels indicates a dysfunct...

Introduction: Prader–Willi syndrome (PWS) is a complex genetic disorder caused by the absence of normal activity in the paternally expressed genes from the chromosome 15q11–q13. PWS is typically characterised by hyperphagia, muscular hypotonia, developmental and cognitive delay, behavioural problems and endocrine abnormalities. Obesity and short stature are common. Controlled studies of hormonal treatment in the transition period are not available.<p class="abste...

Objective: Prader-Willi syndrome (PWS) is a complex genetic disorder. Body composition abnormalities, hyperphagia, progressive obesity and diminished growth hormone secretion are common. In a previous one year GH intervention trial in 19 PWS adults, we have shown beneficial effects on body composition. In the present study we sought to re-evaluate the cohort, with special emphasis on long-term effects of GH treatment.Methods: Fourteen patients, 7 men and...

Czech Republic background: NordiNet® IOS (NCT00960128), a non-interventional study (2006–2016), assessed the effectiveness and safety of real-life treatment with Norditropin. From 23 countries, 2,321 adults with GHD were included; 971, GH-naïve at baseline, were included in the effectiveness analysis set (EAS). Baseline characteristics in the six largest contributing countries were evaluated.Methods: Patient information was ente...

A systematic survey of low S-cortisol levels at the department of clinical chemistry: indications for testing and frequency of undiagnosed adrenal insufficiency.Background: S-cortisol is frequently analyzed at clinical chemistry departments. Low levels of S-cortisol needs to be promptly acted on if the cause is undiagnosed adrenal insufficiency (AI). The causes of S-cortisol testing are however multiple and low levels are necessarily not alarming if foun...

Introduction: PATRO Adults is an ongoing, longitudinal, noninterventional study assessing the long-term safety and efficacy of Omnitrope® (Sandoz; recombinant human growth hormone [rhGH]), among adults with severe growth hormone deficiency (GHD) treated in routine clinical practice in European countries. Omnitrope® was approved by the European Medicines Agency (EMA) in 2006, representing the first biosimilar approved by the EMA. We report the la...

Introduction: The ongoing, international, open, longitudinal, non-interventional study, PATRO Adults, aims to determine the long-term safety and efficacy of Omnitrope® (Sandoz), a recombinant human growth hormone (rhGH). Safety data from an interim analysis are presented here.Methods: Eligible patients are male or female adults who are receiving treatment with Omnitrope® and who have provided informed consent. Patients tre...

Introduction: PATRO adults is an international, longitudinal, non-interventional study of the long-term safety and efficacy of recombinant human growth hormone (rhGH; Omnitrope®, Sandoz). The study will provide additional data on the long-term safety of rhGH in adult patients with severe GH deficiency (GHD). Here, we present safety data from an interim analysis.Methods: Eligible patients are adults who are receiving treatment with Omnitro...

Introduction: Patients with AGHD receiving GH often have comorbidities requiring concomitant treatment. We evaluated patterns of concomitant medication use relative to GH therapy initiation in patients with AGHD.Methods: Patients with AGHD with data on concomitant medications enrolled in NordiNet® IOS (NCT00960128), an international, non-interventional study, receiving GH (Norditropin®, Novo Nordisk A/S, Denmark) therapy w...

Introduction: The clinical significance of the impact of GH on glucose homeostasis in adults with GH deficiency (GHD) remains unclear. We report the impact of 4 years of continuous GH therapy on HbA1c and progression to diabetes.Methods: Data were analysed from patients with adult-onset GHD (>20 years old) enrolled in NordiNet® International Outcome Study (IOS) (NCT00960128), an observational study, and treated with GH (Norditropin<su...